These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1806 related items for PubMed ID: 26289307

  • 21. Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections.
    Gardiner BJ, Golan Y.
    Expert Rev Anti Infect Ther; 2016; 14(5):451-63. PubMed ID: 27042762
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012.
    Sader HS, Castanheira M, Flamm RK, Farrell DJ, Jones RN.
    Antimicrob Agents Chemother; 2014; 58(3):1684-92. PubMed ID: 24379201
    [Abstract] [Full Text] [Related]

  • 25. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.
    Petraitiene R, Petraitis V, Kavaliauskas P, Maung BBW, Khan F, Naing E, Aung T, Zigmantaite V, Grigaleviciute R, Kucinskas A, Stakauskas R, Georgiades BN, Mazur CA, Hayden JA, Satlin MJ, Walsh TJ.
    Antimicrob Agents Chemother; 2020 Mar 24; 64(4):. PubMed ID: 32015048
    [Abstract] [Full Text] [Related]

  • 26. Molecular β-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resistant Subsets.
    Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA, Flamm RK.
    Antimicrob Agents Chemother; 2017 Jun 24; 61(6):. PubMed ID: 28348155
    [Abstract] [Full Text] [Related]

  • 27. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.
    Livermore DM, Meunier D, Hopkins KL, Doumith M, Hill R, Pike R, Staves P, Woodford N.
    J Antimicrob Chemother; 2018 Mar 01; 73(3):648-657. PubMed ID: 29228202
    [Abstract] [Full Text] [Related]

  • 28. Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme.
    Cheng K, Newell P, Chow JW, Broadhurst H, Wilson D, Yates K, Wardman A.
    Drug Saf; 2020 Aug 01; 43(8):751-766. PubMed ID: 32602065
    [Abstract] [Full Text] [Related]

  • 29. Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases.
    Meschiari M, Asquier-Khati A, Tiseo G, Luque-Paz D, Murri R, Boutoille D, Falcone M, Mussini C, Tattevin P, Italian Society of Infectious and Tropical Diseases (SIMIT), and the French Society of Infectious Diseases (SPILF).
    Int J Antimicrob Agents; 2024 Jul 01; 64(1):107186. PubMed ID: 38688353
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.
    Stone GG, Bradford PA, Yates K, Newell P.
    J Antimicrob Chemother; 2017 May 01; 72(5):1396-1399. PubMed ID: 28088768
    [Abstract] [Full Text] [Related]

  • 32. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
    Cho JC, Fiorenza MA, Estrada SJ.
    Pharmacotherapy; 2015 Jul 01; 35(7):701-15. PubMed ID: 26133315
    [Abstract] [Full Text] [Related]

  • 33. Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam.
    Li J, Lovern M, Riccobene T, Carrothers TJ, Newell P, Das S, Talley AK, Tawadrous M.
    Antimicrob Agents Chemother; 2020 Mar 24; 64(4):. PubMed ID: 32015049
    [Abstract] [Full Text] [Related]

  • 34. A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia.
    Qin X, Tran BG, Kim MJ, Wang L, Nguyen DA, Chen Q, Song J, Laud PJ, Stone GG, Chow JW.
    Int J Antimicrob Agents; 2017 May 24; 49(5):579-588. PubMed ID: 28363526
    [Abstract] [Full Text] [Related]

  • 35. Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012-2014.
    Sader HS, Castanheira M, Flamm RK, Huband MD, Jones RN.
    Surg Infect (Larchmt); 2016 Aug 24; 17(4):473-8. PubMed ID: 27104633
    [Abstract] [Full Text] [Related]

  • 36. Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development.
    Sy SKB, Zhuang L, Sy S, Derendorf H.
    Clin Pharmacokinet; 2019 May 24; 58(5):545-564. PubMed ID: 30097887
    [Abstract] [Full Text] [Related]

  • 37. Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam.
    De la Calle C, Rodríguez O, Morata L, Marco F, Cardozo C, García-Vidal C, Río AD, Feher C, Pellicé M, Puerta-Alcalde P, Mensa J, Soriano A, Martínez JA.
    Int J Antimicrob Agents; 2019 Apr 24; 53(4):520-524. PubMed ID: 30471403
    [Abstract] [Full Text] [Related]

  • 38. Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014.
    Hackel M, Kazmierczak KM, Hoban DJ, Biedenbach DJ, Bouchillon SK, de Jonge BL, Stone GG.
    Antimicrob Agents Chemother; 2016 Aug 24; 60(8):4677-83. PubMed ID: 27216054
    [Abstract] [Full Text] [Related]

  • 39. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.
    Bush K.
    Int J Antimicrob Agents; 2015 Nov 24; 46(5):483-93. PubMed ID: 26498989
    [Abstract] [Full Text] [Related]

  • 40. Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.
    Hidalgo JA, Vinluan CM, Antony N.
    Drug Des Devel Ther; 2016 Nov 24; 10():2379-86. PubMed ID: 27528799
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 91.